Sanofi Business Model Canvas

Partnerships with WHO (194 member states), Gavi (which since 2000 has helped immunize about 888 million children and prevented some 15 million deaths), BARDA and national health ministries enable Sanofi to scale vaccine programs through funding and joint demand forecasting. These alliances support equitable access and cold-chain initiatives, strengthen pandemic preparedness via jointly funded programs, and tender frameworks deliver more predictable volumes and pricing for supply planning.

Sanofi leverages biotech alliances, academic consortia and public health partners to derisk pipelines and scale vaccines, backing over 200 academic ties and an R&D spend of about €6.6bn in 2024. CROs/CDMOs and digital partners enable flexible manufacturing and AI-driven trials; 2024 sales ~€44.3bn across 100+ countries.

Operate GMP facilities for biologics, vaccines and small molecules across Sanofi's global network, supported by roughly 91,000 employees (2024). Stringent QC/QA, serialization and cold-chain integrity (ultra-cold to 2–8°C) protect product quality. Production is scaled to meet tenders and seasonal demand, and continuous process verification improves reliability and yields.

Discover targets and drive hit-to-lead with integrated omics, AI and biomarkers; Sanofi spent about €6.2bn on R&D in 2024 and employs ~91,000. Run global Phase I–IV trials and HEOR to secure reimbursement across 100+ jurisdictions and 50+ HTA bodies. Operate GMP biologics/small-molecule manufacturing, cold-chain logistics and omnichannel launches to maximize access.

Patents, trade secrets and regulatory exclusivities underpin Sanofi’s innovation moat, supported by an estimated €5.6bn R&D spend in 2024. Trial datasets and real‑world evidence from hundreds of studies inform development and market access. Integrated data platforms power safety surveillance and dynamic label management. Strong brand equity boosts pricing power and market share.

Sanofi’s key resources include multidisciplinary R&D teams supporting 40+ clinical programs in 2024, platform technologies (biologics, mRNA, antibody engineering) and €6.2bn R&D spend. A global GMP manufacturing network with cold-chain and redundant sites secures supply. Patent portfolios, trial datasets and strong brands underpin market access and lifecycle value; 2024 sales €47.6bn.

Sanofi leverages a global network present in more than 100 countries and ~100,000 employees to ensure large-scale manufacturing and redundant sites for continuity. Cold-chain competence preserves product integrity with typical vaccine storage at 2–8°C. Agile capacity supports seasonal and pandemic surges, while targeted service levels and inventory management maintain high availability and reduce shortages and disruptions.

Proven therapies and vaccines: 300+ ongoing trials, 150+ real-world studies, 170+ country approvals and 30+ GMP sites ensure quality and trust. Integrated care across prevention, acute and chronic portfolios; 100,000 employees in 100+ countries enable scale and continuity. Robust pipeline: 30+ clinical-stage programs in 2024 with next-gen biologics and mRNA platforms.

Medical education programs, MSL interactions and peer-reviewed scientific materials support informed prescribing and real-world use of Sanofi therapies, with Sanofi employing roughly 45,000 people globally to sustain these efforts. Advisory boards capture frontline insights to shape development and access strategies. Clinical tools and adherence resources improve patient management and outcomes. Responsive medical information services resolve HCP queries rapidly.

Dedicated government teams secure >1bn vaccine doses/year (2024) and multi-year tenders; Sanofi group sales €44.1bn (2024) support account management across channels. HTA dossiers and RWE drive payer access in 25 countries; risk-share deals and quarterly touchpoints sustain reimbursement. Patient services (45,000 staff) lift persistence +30%, cut abandonment ~50%, digital reminders +20%.

Distributors, national chains and independent pharmacies secure Sanofi product availability across over 100 countries, combining broad reach with local penetration. Service-level agreements (SLAs) govern replenishment, returns and target on-time fill and stock accuracy metrics. Category management programs drive consumer health growth through assortment and promotion optimization. Serialization aligned with EU FMD and US DSCSA ensures traceability and supply integrity.

Sanofi uses public tenders and hospital procurement across 100+ countries to secure volume and multi-year contracts, supported by Pasteur's vaccine footprint. Distributors, national chains and provider portals ensure broad availability while e-commerce and analytics grow OTC margins. Omnichannel field teams (MSLs + reps) and digital tools leverage Sanofi's 2024 scale: €44.5bn revenue and ~90,000 employees.

Hospitals and provider networks are acute-care buyers for oncology, immunology and specialty products, representing about 6,100 US hospitals (AHA 2024). They prioritize clinical efficacy, operational fit and total cost; formulary and P&T committees drive adoption decisions. Hospitals demand dependable supply chains and bundled support services—training, reimbursement assistance and 24/7 logistics—to ensure uninterrupted patient care.

Governments/public health (DTP3 ~81% 2023 WHO) buy vaccines via multi-year tenders; payers/HTA (global pharma spend ~$1.6T 2024 IQVIA) drive access via value assessments; hospitals (≈6,100 US hospitals AHA 2024) require reliable supply and services; specialists and patients demand strong evidence, safety, affordability and digital support.

Sanofi allocates a significant portion of commercial costs to a global field force (≈110,000 employees company-wide in 2024) and omnichannel campaigns that complement medical education and conference participation, with conference materials and digital assets centralized to improve ROI. Patient support and access services are scaled to millions of patients, while dedicated account teams manage tenders and payer relations tied to Sanofi’s 2024 net sales of about €45 billion.

Sanofi 2024 cost base centers on R&D (~€6.8bn), large biologics/vaccines COGS (25–40% of product revenue) and cold-chain distribution (10–15% uplift). Commercial spend supports ≈110,000 employees and global field force tied to €45bn 2024 net sales. Milestones/royalties and regulatory/pharmacovigilance programs add material variable and fixed overhead.

Sanofi's consumer healthcare (OTC) revenue comes from established brands sold through traditional retail and growing e-commerce channels, where online penetration increasingly complements pharmacy and supermarket distribution. Category growth and strong brand equity sustain higher gross margins, while targeted promotions and category management shift market share across channels. Expansion in emerging markets extends reach and supports volume-led revenue diversification.

Prescription medicines drove group revenue at €45.8 billion in 2024; volume, price and lifecycle extensions sustain growth. Vaccines generated ~€6.5 billion (~15% of group) via public tenders and seasonal programs. Consumer healthcare grows via retail and e-commerce while collaborations, milestones, royalties and contract manufacturing provide de-risking and long-tail cash flows.